Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hiroki Ikezawa
Observed names:
H. Ikezawa,
H., Ikezawa,
Ikezawa, Hiroki
Institution:
Eisai (Japan)
Observed institutions:
Shikoku Cancer Center,
Eisai (Japan)
ORCID:
0009-0008-3610-3331
Observed ORCID:
0009-0008-3610-3331
OpenAlex ID:
A5065715625
A Phase II Study of the Safety and Efficacy of Lenvatinib in Patients with Advanced Thyroid Cancer
2019
·
Shunji Takahashi
, Naomi Kiyota
, et al.
·
Future Oncology
·
150
PDF
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors
2021
·
Toshio Shimizu
, Yutaka Fujiwara
, et al.
·
Clinical Cancer Research
·
118
Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
2020
·
Makoto Ueno
, Masafumi Ikeda
, et al.
·
BMC Cancer
·
100
PDF
A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117.
2020
·
Masatoshi Kudo
, Masafumi Ikeda
, et al.
·
Journal of Clinical Oncology
·
95
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
2021
·
Richard S. Finn
, Masatoshi Kudo
, et al.
·
Clinical Cancer Research
·
86
PDF
A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
2021
·
Xiangqian Zheng
, Zhengang Xu
, et al.
·
Clinical Cancer Research
·
48
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial
2024
·
Seiji Niho
, Jun Sato
, et al.
·
Lung Cancer
·
28
PDF
Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study
2018
·
Nobuaki Matsubara
, Yoichi Naito
, et al.
·
International Journal of Urology
·
22
PDF
Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial.
2022
·
Shin Nishio
, Mayu Yunokawa
, et al.
·
Journal of Clinical Oncology
·
21
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
2020
·
Chung-Han Lee
, Robert J. Motzer
, et al.
·
British Journal of Cancer
·
21
PDF
Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting
2020
·
Kenichi Inoue
, Masato Takahashi
, et al.
·
Investigational New Drugs
·
20
PDF
Abstract CT061: A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
2019
·
Masafumi Ikeda
, Max W. Sung
, et al.
·
Cancer Research
·
18
Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan
2021
·
Masato Takahashi
, Kenichi Inoue
, et al.
·
Breast Cancer
·
17
PDF
A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors
2019
·
Toshihiko Doi
, Takeshi Aramaki
, et al.
·
Investigational New Drugs
·
17
PDF
Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA).
2024
·
Junji Furuse
, Bo Jiang
, et al.
·
Journal of Clinical Oncology
·
16
PDF
Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
2022
·
Masatoshi Eto
, Toshio Takagi
, et al.
·
Cancer Medicine
·
14
PDF
A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results
2017
·
M. Ikeda
, T. Sasaki
, et al.
·
Annals of Oncology
·
12
Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study
2025
·
Lin Shen
, Huaxin Duan
, et al.
·
Japanese Journal of Clinical Oncology
·
9
PDF
First‐in‐human study of E7130 (a tumor microenvironment‐ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose‐escalation part
2023
·
Toshihiko Doi
, Nobuaki Matsubara
, et al.
·
Cancer
·
8
Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first‐in‐human phase I study
2024
·
Chigusa Morizane
, Makoto Ueno
, et al.
·
Cancer Science
·
7
PDF
First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors.
2019
·
Toshio Shimizu
, Yutaka Fujiwara
, et al.
·
Journal of Clinical Oncology
·
7
A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma
2026
·
Masafumi Ikeda
, Masatoshi Kudo
, et al.
·
Liver Cancer
·
6
PDF
Pharmacokinetic Study of Lenvatinib in Chinese Patients with Solid Tumors
2021
·
Dan Liu
, Lei Liu
, et al.
·
Future Oncology
·
6
Abstract CT061: A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
2019
·
Masafumi Ikeda
, Max W. Sung
, et al.
·
Clinical Trials
·
6
Pharmacotherapy decision-making among patients with breast cancer in Japan: results of an online survey
2019
·
Chikako Shimizu
, Yukinori Sakata
, et al.
·
Breast Cancer
·
6
Show more works
View as search
Works count:
55
Citation count:
889
H-index:
15
I10-index:
17
Year
Topic
Type